Announcements
- Basilea shareholders approve all proposals of the board of directors at the annual general meeting
- Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats
- Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
- Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-Wirkstoffklasse
- Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekannt
- Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
- Anhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
- Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
- Basilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-Portfolio
More ▼
Key statistics
On Thursday, Basilea Pharmaceutica AG Allschwil (0QNA:LSE) closed at 40.25, 25.00% above the 52 week low of 32.20 set on Jan 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 40.25 |
Average volume | 6.45k |
---|---|
Shares outstanding | 13.10m |
Free float | 13.09m |
P/E (TTM) | 46.27 |
Market cap | 531.26m CHF |
EPS (TTM) | 0.8765 CHF |
Data delayed at least 20 minutes, as of Apr 25 2024 17:52 BST.
More ▼